Lördag 2 Augusti | 08:06:17 Europe / Stockholm

Kalender

Est. tid*
2025-08-07 N/A X-dag halvårsutdelning AZN 76.700002
2025-07-29 - Kvartalsrapport 2025-Q2
2025-04-29 - Kvartalsrapport 2025-Q1
2025-04-11 - Årsstämma
2025-02-20 - X-dag halvårsutdelning AZN 167.999995
2025-02-06 - Bokslutskommuniké 2024
2024-11-12 - Kvartalsrapport 2024-Q3
2024-08-08 - X-dag halvårsutdelning AZN 77.600002
2024-07-25 - Kvartalsrapport 2024-Q2
2024-04-25 - Kvartalsrapport 2024-Q1
2024-04-11 - Årsstämma
2024-02-22 - X-dag halvårsutdelning AZN 155.999994
2024-02-08 - Bokslutskommuniké 2023
2023-11-09 - Kvartalsrapport 2023-Q3
2023-08-10 - X-dag halvårsutdelning AZN 71.799999
2023-07-28 - Kvartalsrapport 2023-Q2
2023-04-27 - Årsstämma
2023-04-27 - Kvartalsrapport 2023-Q1
2023-02-23 - X-dag halvårsutdelning AZN 162.800002
2023-02-09 - Bokslutskommuniké 2022
2022-11-10 - Kvartalsrapport 2022-Q3
2022-08-11 - X-dag halvårsutdelning AZN 76.4
2022-07-29 - Kvartalsrapport 2022-Q2
2022-04-29 - Årsstämma
2022-04-29 - Kvartalsrapport 2022-Q1
2022-02-24 - X-dag halvårsutdelning AZN 145.299995
2022-02-10 - Bokslutskommuniké 2021
2021-11-12 - Kvartalsrapport 2021-Q3
2021-08-12 - X-dag halvårsutdelning AZN 64.8
2021-07-29 - Kvartalsrapport 2021-Q2
2021-05-11 - Årsstämma
2021-04-30 - Kvartalsrapport 2021-Q1
2021-02-25 - X-dag halvårsutdelning AZN 137.399995
2021-02-11 - Bokslutskommuniké 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-08-13 - X-dag halvårsutdelning AZN 69.599998
2020-07-30 - Kvartalsrapport 2020-Q2
2020-04-29 - Årsstämma
2020-04-29 - Kvartalsrapport 2020-Q1
2020-02-27 - X-dag halvårsutdelning AZN 146.399999
2020-02-14 - Bokslutskommuniké 2019
2019-10-24 - Kvartalsrapport 2019-Q3
2019-08-08 - X-dag halvårsutdelning AZN 71.899998
2019-07-25 - Kvartalsrapport 2019-Q2
2019-04-26 - Årsstämma
2019-04-26 - Kvartalsrapport 2019-Q1
2019-02-28 - X-dag halvårsutdelning AZN 146.800005
2019-02-14 - Bokslutskommuniké 2018
2018-11-08 - Kvartalsrapport 2018-Q3
2018-08-09 - X-dag halvårsutdelning AZN 68.400002
2018-07-26 - Kvartalsrapport 2018-Q2
2018-05-18 - Årsstämma
2018-05-18 - Kvartalsrapport 2018-Q1
2018-02-15 - X-dag halvårsutdelning AZN 133.599997
2018-02-02 - Bokslutskommuniké 2017
2017-11-09 - Kvartalsrapport 2017-Q3
2017-08-10 - X-dag halvårsutdelning AZN 68.900001
2017-07-27 - Kvartalsrapport 2017-Q2
2017-04-27 - Årsstämma
2017-04-27 - Kvartalsrapport 2017-Q1
2017-02-16 - X-dag halvårsutdelning AZN 150.199997
2017-02-02 - Bokslutskommuniké 2016
2016-11-10 - Kvartalsrapport 2016-Q3
2016-08-11 - X-dag halvårsutdelning AZN 68.699998
2016-07-28 - Kvartalsrapport 2016-Q2
2016-04-29 - Årsstämma
2016-04-29 - Kvartalsrapport 2016-Q1
2016-02-18 - X-dag halvårsutdelning AZN 145.555556
2016-02-04 - Bokslutskommuniké 2015
2015-11-05 - Kvartalsrapport 2015-Q3
2015-08-13 - X-dag halvårsutdelning AZN 63.88889
2015-07-30 - Kvartalsrapport 2015-Q2
2015-04-24 - Årsstämma
2015-04-24 - Kvartalsrapport 2015-Q1
2015-02-19 - X-dag halvårsutdelning AZN 138.888896
2015-02-05 - Bokslutskommuniké 2014
2014-11-06 - Kvartalsrapport 2014-Q3
2014-08-13 - X-dag halvårsutdelning AZN 59
2014-07-31 - Kvartalsrapport 2014-Q2
2014-04-24 - Årsstämma
2014-04-24 - Kvartalsrapport 2014-Q1
2014-02-19 - X-dag halvårsutdelning AZN 129.777777
2014-02-06 - Bokslutskommuniké 2013
2013-10-31 - Kvartalsrapport 2013-Q3
2013-08-14 - X-dag halvårsutdelning AZN 65.777779
2013-08-01 - Analytiker möte 2013
2013-08-01 - Kvartalsrapport 2013-Q2
2013-04-25 - Årsstämma
2013-04-25 - Kvartalsrapport 2013-Q1
2013-02-13 - X-dag halvårsutdelning AZN 133.888888
2013-01-31 - Bokslutskommuniké 2012
2012-10-25 - Analytiker möte 2012
2012-10-25 - Kvartalsrapport 2012-Q3
2012-08-08 - X-dag halvårsutdelning AZN 64.555556
2012-07-26 - Kvartalsrapport 2012-Q2
2012-04-26 - Årsstämma
2012-04-26 - Kvartalsrapport 2012-Q1
2012-02-15 - X-dag halvårsutdelning AZN 137.333333
2012-02-02 - Bokslutskommuniké 2011
2011-10-27 - Kvartalsrapport 2011-Q3
2011-08-03 - X-dag halvårsutdelning AZN 57.666665
2011-07-28 - Kvartalsrapport 2011-Q2
2011-04-28 - Årsstämma
2011-04-28 - Kvartalsrapport 2011-Q1
2011-02-02 - X-dag halvårsutdelning AZN 129.666662
2011-01-27 - Bokslutskommuniké 2010
2010-10-28 - Kvartalsrapport 2010-Q3
2010-08-04 - X-dag halvårsutdelning AZN 49.888888
2010-07-29 - Kvartalsrapport 2010-Q2
2010-04-29 - Kvartalsrapport 2010-Q1
2010-02-03 - X-dag halvårsutdelning AZN 117.111111
2010-01-28 - Bokslutskommuniké 2009
2009-10-29 - Kvartalsrapport 2009-Q3
2009-08-05 - X-dag halvårsutdelning AZN 40
2009-07-30 - Kvartalsrapport 2009-Q2
2009-04-30 - Årsstämma
2009-04-30 - Kvartalsrapport 2009-Q1
2009-02-04 - X-dag halvårsutdelning AZN 116.444444
2008-08-06 - X-dag halvårsutdelning AZN 30.888888
2008-02-06 - X-dag halvårsutdelning AZN 75.2222222
2007-08-08 - X-dag halvårsutdelning AZN 28.111111
2007-02-07 - X-dag halvårsutdelning AZN 70
2006-08-09 - X-dag halvårsutdelning AZN 32.562658

Beskrivning

LandStorbritannien
ListaFTSE 100
SektorHälsovård
IndustriLäkemedel & Handel
AstraZeneca är ett globalt läkemedelsbolag med fokus på forskning, utveckling och marknadsföring av receptbelagda läkemedel, primärt för behandling av sjukdomar inom terapiområdena som berör andningsvägar, hjärta/kärl/metabolism och cancer. Utöver huvudverksamheten är bolaget även aktiva inom autoimmunitet, neurovetenskap och infektion. AstraZeneca är verksamt inom samtliga globala regioner och har sitt huvudkontor i Cambridge, Storbritannien.
2025-07-24 08:05:25

Gefurulimab dual-binding nanobody demonstrated statistically significant and clinically meaningful improvement in functional activities of daily living in adults with generalised myasthenia gravis in PREVAIL Phase III trial.

Once-weekly self-administered subcutaneous C5 inhibitor showed statistically significant and clinically meaningful reduction in disease severity at week 26.

Positive high-level results from a global, randomised, double-blind, placebo-controlled Phase III trial in adults with anti-acetylcholine receptor (AChR) antibody-positive (Ab+) generalised myasthenia gravis (gMG) showed that gefurulimab met its primary and all secondary endpoints. Data demonstrated a statistically significant and clinically meaningful improvement from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score at week 26 compared to placebo.

gMG is a rare, debilitating, chronic, autoimmune neuromuscular disease that leads to a loss of muscle function and severe weakness.1 Those living with gMG may initially experience slurred speech, double vision, droopy eyelids and weakness, with symptoms becoming more severe as the disease progresses, including extreme fatigue, difficulty swallowing, choking and respiratory failure.2,3

Kelly Gwathmey, MD, Associate Professor of Neurology, Chief of Neuromuscular Division, Virginia Commonwealth University, Richmond, VA, Vice Chair of the MGFA Medical & Scientific Advisory Council and principal investigator in the trial, said: "Rapidly fluctuating symptoms and the unpredictable disability associated with gMG can affect nearly everyaspect of a patient's life, making early intervention and sustained disease control a critical treatment goal. A once-weekly, self-administered C5 treatment option would offer patients greater convenience and independence in managing their condition, empowering them to have more control over their therapy."

Marc Dunoyer, Chief Executive Officer, Alexion, AstraZeneca Rare Disease, said: "Building on Alexion's pioneering leadership in gMG, these positive results from the PREVAIL Phase III trial demonstrate the potential for gefurulimab to offer rapid and sustained disease control for this patient community. These data, reflecting patient participation across 20 countries, reinforce the established safety profile and efficacy of C5 inhibition and show the potential for gefurulimab as a first line biologic, with the convenience of a self-administered option."

Gefurulimab was well-tolerated, and the safety profile was consistent with previous trials of C5 inhibitors in gMG with no new safety signals observed. These data will be presented at a forthcoming medical meeting and shared with global regulatory authorities.

Notes

gMG
gMG is a rare autoimmune disorder characterised by loss of muscle function and severe muscle weakness.1

Eighty-five percent of people with gMG are AChR antibody-positive meaning they produce specific antibodies (anti-AChR) that bind to signal receptors at the neuromuscular junction (NMJ), the connection point between nerve cells and the muscles they control.4 This binding activates the complement system, causing the immune system to attack the NMJ, leading to inflammation and a breakdown in communication between the brain and the muscles.5

gMG can occur at any age, but it most commonly begins for women before the age of 40 and for men after the age of 60.6 Initial symptoms may include slurred speech, double vision, droopy eyelids and lack of balance; these can often lead to more severe symptoms as the disease progresses such as, impaired swallowing, choking, extreme fatigue and respiratory failure.2,3

Gefurulimab
Gefurulimab, an investigational complement C5 inhibitor, is a novel dual-binding nanobody optimised for subcutaneous self-administration in development as a treatment for AChR-Ab+ gMG. The investigational medication works by binding to the C5 protein in the terminal complement cascade, a part of the body's immune system. When activated in an uncontrolled manner, the complement cascade over-responds, leading the body to attack its own healthy cells. Gefurulimab's concurrent binding to serum albumin provides an extended half-life, enabling once-weekly dosing. Gefurulimab has been granted Orphan Drug Designation in the US for the treatment of myasthenia gravis. 

PREVAIL (ALXN1720-MG-301)
PREVAIL (ALXN1720-MG-301) is a global, Phase III, randomised, double-blind, placebo-controlled, parallel, multicentre study evaluating the safety and efficacy of gefurulimab in adults with generalised myasthenia gravis (gMG). The trial enrolled 260 patients from 20 countries across North America, Europe, Asia and the Pacific region. Participants were required to have a confirmed myasthenia gravis diagnosis at least three months prior to the screening visit with a positive serological test for autoantibodies against AChR and Myasthenia Gravis Foundation of America Clinical Classification Class II to IV at screening.7

Patients were randomised 1:1 to receive gefurulimab or placebo for a total of 26 weeks in the randomised controlled treatment period. Patients received a single weight-based loading dose on Day 1, followed by regular weight-based maintenance dosing beginning on Day 8 and once every week thereafter. The primary endpoint of the change from baseline in the Myasthenia Gravis Activities of Daily Living (MG-ADL) total score, a patient-reported scale that assesses patients' abilities to perform daily activities, was assessed at week 26 along with multiple secondary endpoints evaluating improvement in disease-related measures.7

Patients who completed the randomised controlled treatment period were eligible to continue into an open-label extension period evaluating the safety and efficacy of gefurulimab, which is ongoing.7

Alexion
Alexion, AstraZeneca Rare Disease, is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and delivery of life-changing medicines. A pioneering leader in rare disease for more than three decades, Alexion was the first to translate the complex biology of the complement system into transformative medicines, and today it continues to build a diversified pipeline across disease areas with significant unmet need, using an array of innovative modalities. As part of AstraZeneca, Alexion is continually expanding its global geographic footprint to serve more rare disease patients around the world. It is headquartered in Boston, US.

AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca.

Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

References

  1. Jung-Plath W, et al. Assessment of myasthenia gravis patients' quality of life. The Journal of Neurological and Neurosurgical Nursing. 2023;12(2):74-83.
  2. Catalin J, et al. Clinical presentation of myasthenia gravis. Thymus. 2019.
  3. Farid ZR, et al. Factors affecting generalization of ocular myasthenia gravis. Sriwijaya Journal of Ophthalmology. 2020;3(2):48-54.
  4. Lazaridis K, et al. Myasthenia gravis: autoantibody specificities and their role in MG management. Front Neurol. 2020;11:596981.
  5. Huang YF, et al. Visualization and characterization of complement activation in acetylcholine receptor antibody seropositive myasthenia gravis. Muscle Nerve. 2024.
  6. Cavanagh N, et al. Exploring the impairments and allied health professional utilization in people with myasthenia gravis: a cross-sectional study. J Clin Neurosci. 2023;114:9-16.
  7. ClinicalTrials.gov. Safety and efficacy of ALXN1720 in adults with generalized myasthenia gravis. NCT Identifier: NCT05556096. Available here. Accessed July 2025.